Stockreport

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting [Yahoo! Finance]

Incyte Corporation  (INCY) 
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
PDF Late-breaking data presentation at ASH will feature results from the Phase 3 inMIND study evaluating tafasitamab in follicular lymphoma (FL); data to be highlighted dur [Read more]